
How BRCA Mutations Are Linked to Prostate Cancer
BRCA prostate cancer can change everything from screening to treatment—BRCA2 carries the highest risk, and a mutation may open targeted PARP therapy.

BRCA prostate cancer can change everything from screening to treatment—BRCA2 carries the highest risk, and a mutation may open targeted PARP therapy.

A prostate cancer diet works through your overall pattern and weight, not any single food — and some supplements can do more harm than good.

Prostate cancer statistics for 2026 show a 1 in 8 lifetime risk — but only 1 in 44 men die of it. Here's what the latest US numbers really mean.

Prostate cancer survival rates vary by stage — from over 99% for localized disease to 38% once it spreads. Here's what the numbers mean for you.

Metastatic prostate cancer has a 38% 5-year survival rate—but that average doesn't predict any one person's outlook. Here's how to read it.

Prostate cancer recurrence usually shows up first as a rising PSA — not symptoms. Here's how doctors read the threshold, doubling time, and PSMA PET scans.

Leaking urine after prostatectomy is expected — and usually temporary. Here's the honest recovery timeline, from catheter removal to the 12-month mark.

Erectile dysfunction after prostate cancer is common but often manageable — and recovery odds rise sharply for younger men with nerve-sparing surgery.

Choosing between prostate cancer surgery and radiation? Survival is nearly the same for both—what differs is the side-effect trade-off.

PARP inhibitors work only against prostate cancers with BRCA or HRR mutations—a December 2025 FDA approval added a BRCA2 hormone-sensitive option.